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Abstract. The purpose of our study was to assess the 
prevalence and prognostic significance of HPV infection as 
well as K-ras codon 12 point mutations in lung cancer. 
Patients diagnosed with lung carcinoma between 1988 and 
1992 (N=99) were selected. HPV detection and typing was 
performed by PCR from paraffin-embedded tissues, while 
mutations in codon 12 of K-ras gene were detected using the 
restriction fragment length polymorphism (RFLP) analysis. The 
prevalence of HPV infection was 15%, while K-ras codon 12 
point mutations were found in 18% of the specimens examined. 
In 50% of the HPV-positive cases, K-ras gene mutation co­
existed. HPV 18 was the most frequent type. No correlation 
was found between K-ras mutation and HPV infection with 
sex, age and clinical outcome of the patient, or the histological 
type and the differentiation grade of the tumor. An association 
was found between K-ras codon 12 point mutations and the 
stage of the tumor, occurring more frequently at stage III 
(p=0.037). Infection with potentially oncogenic HPV types 
could co-operate with K-ras gene activation in the 
progression of the disease, since K-ras activation by point 
mutations seems to be a late event in lung carcinogenesis. 
Introduction 
Carcinoma of the lung has become increasingly frequent during 
the past 50 years. It is now the leading cause of cancer mortality 
in the Western world. This is due not only to increased 
recognition through better radiographic, bronchoscopic and 
cytologic techniques but also to an actual rise in incidence. 
Carcinoma of the lung is associated with various environmental 
factors, most importantly smoking and asbestos exposure (1-3). 
However, many heavy smokers remain free of this disease or 
other smoking-related cancers. It has been suggested that 
genetic factors may also contribute to the development of lung 
carcinoma. So far, no classical linkage analysis that correlates 
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incidence of the disease with the inheritance of genetic markers, 
has been reported for lung cancer (4). 
During recent years, a great deal of data has been 
accumulated on the role of HPV in the development of 
carcinoma of different anatomical sites of the body. Molecular 
biology techniques have disclosed that there are at least 73 
different types and several subtypes of HPV (5,6). Most viral 
types are observed in anogenital tract and skin lesions (7). 
HPV has also been detected in carcinomas of the oral and 
nasal cavity (8), the male urethra (9), the urinary bladder (ΙΟ­
Ι 2), the esophagus and the respiratory tract. 
With regard to the upper respiratory tract, many types of 
HPV (6, 11,16, 30) have been detected in laryngeal carcinomas 
(13,14). Clear etiological evidence indicated that in laryngeal 
papillomas infection with HPV types 16 and 18 was associated 
with progression to malignant lesions, whereas HPV types 6b 
and 11 were usually associated with benign lesions (15). 
In the lower respiratory tract, the causative role of HPV was 
suggested by morphological data already in 1979: cytological 
and histological similarities with lesions from uterine cervix 
condylomas were described in about 30% of bronchial 
epithelium next to invasive bronchial squamous cell carcinoma 
(16) or well differentiated squamous cell carcinoma (17,18). 
HPV sequences have also been demonstrated in primary lung 
squamous cell carcinomas (19-21). Patients with squamous 
cell papillomas exhibiting HPV 16 or 18 positivity are at high 
risk for the development of squamous cell carcinoma. Virus 
typing seems to be a better prognostic indicator than grading of 
dysplasia or age relationship, while virus typing by the PCR is 
more sensitive compared with in situ hybridization (ISH) (22). 
Moreover, molecular tumor markers may offer clinically 
useful tools for diagnostic and prognostic purposes in lung 
cancer (23). Ras genes are often found activated in a variety of 
tumor types, although the incidence varies greatly. K-ras gene 
is by far the most frequently involved in lung tumors (24-27). 
Point mutations of the K-ras gene were observed primarily in 
patients with a habit of smoking. Patients with K-ras positive 
tumors have a significantly poorer prognosis than patients with 
K-ras negative tumors (28). There is evidence that K-ras gene 
may serve as a genetic marker not only in the early detection 
of lung cancer (29) but also in the differential diagnosis of 
recurrence or metastasis versus second primaries of the lung 
(30). In addition strong overexpression of K-ras gene has been 
reported in a high incidence of non-small cell lung carcinomas 
(31). 
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In the current study, HPV detection and typing as well as 
detection of K-ras gene mutations was performed in 99 cases 
of lung carcinoma from paraffin-embedded tissues employing 
the PCR technique. 15% of the specimens were found positive 
for HPV, while 18% carried mutation in the codon 12 of the 
K-ras gene. It was also examined whether such alterations 
correlate with clinicopathological parameters or clinical 
outcome. 
Materials and methods 
Patients and specimens. The primary neoplasm specimens 
were excised either by surgical lobectomy or pneumonectomy 
and fixed in neutral formalin, at Sismanoglion General Hospital, 
Athens, between 1988-1992. Hematoxylin-eosin stained sections 
from all paraffin-embedded tissues examined, were reviewed 
to reconfirm the tumor type, differentiation grade while re­
presentative blocks (one per case) were selected for further 
analysis. 
Eighty-seven of the 99 patients were smokers, 3 were non-
smokers and for the remaining 9 no reliable data on smoking 
habits were available. Most of the smokers were heavy smokers 
(>60 py). The age range was 44-77 years, and the mean age 
62.8 years. 
DNA extraction. Five or six 10 μηι thick sections from formalin-
fixed, paraffin-embedded tissues were lysed in 400 μΐ digestion 
buffer, containing 100 mM NaCl, 10 mM Tris-HCl, 25 raM 
EDTA, 0.5% SDS pH 8.0, 0.1 mg/ml proteinase K. Samples 
were incubated for 24 h at 37°C. Fresh proteinase Κ was added 
and the incubation was continued for another 24 h. The samples 
were then extracted once with phenol/chloroform and once 
with chloroform. DNA was precipitated with the addition of 
20 μΐ 5 M NaCl and 1 ml ethanol, recovered by centrifugation 
for 15 min at 4°C, washed once with cold 70% ethanol and 
resuspended in 30 μΐ double distilled water. 
Oligonucleotide primers and PCR amplification. For the 
detection and type distinction of the HPV, multiplex PCR was 
employed using four pairs of primers stimultaneously (for HPV 
types 11, 16, 18 and 33), providing different lengths of amplified 
DNA for each virus type (32), while the results were confirmed 
using the general primers GP5 and GP6 (33) followed by Rsal 
digestion giving a different pattern for each type (34). The 
oligonucleotides used for K-ras have been previously described 
(35). One μΐ of the extracted DNA of each sample was amplified 
in a reaction solution of 50 μΐ containing 20 mM (NH4)2S04, 
2.0 mM MgCl2, 75 mM Tris-HCl pH 9.0, 0.01% (w/v) Tween, 
200 μΜ of each dNTP, 0.5 μΜ of each primer and 1.25 U Taq 
polymerase (Advanced Biotechnologies). The mixture was 
heated for 1 min at 95°C, and then subjected to 35 cycles of 
amplification under the following conditions. 
HPV amplification: Using the specific set of primers each 
cycle consisted of 50 sec at 94 °C, 40 sec at 56°C and 45 sec at 
72°C, increasing the elongation time 1 sec per cycle. To 
establish type specificity of primer-directed amplification, each 
set of primers was tested with template plasmid DNA of the 
five HPV types 6b, 11, 16, 18 and 33. 
Using the general primers GP5 and GP6 each cycle 
consisted of 50 sec at 94°C, 50 sec at 52°C and 40 sec at 72°C, 
increasing the elongation time 1 sec per cycle. 
K-ras amplification: Each cycle consisted of a denaturation 
step at 94°C for 50 sec, an annealing step at 58°C for 45 sec 
and an elongation step at 72°C for 50 sec, increasing the 
elongation time 1 sec per cycle. 
RFLP analysis. HPV-general primers: Confirmation of the 
typing was achieved by digestion of the amplification products 
with 30 U of Rsal giving a different pattern for each type. 
Digestion products were electrophoresed through a 10% 
Polyacrylamide gel. As control the amplified product of plasmid 
DNA of the HPV types 6b, 11, 16, 18 and 33 were used. 
K-ras; 10-20 μΐ were digested for 3 h with 30 U of BstNI. 
Digestion products were electrophoresed through an 8% 
Polyacrylamide gel. Gels were stained with ethidium bromide 
and photographed on a UV light transilluminator. Enzymes 
were supplied by New England Biolabs and the conditions 
followed for digestions were those recommended by the 
supplier. Incubation temperatures were 37°C for Rsal and 
60°C for BstNI. 
Statistical analysis. The presence of HPV and mutations at 
codon 12 of K-ras gene were analysed for significant correlation 
with histological type, grade, TNM stage and age at day of 
operation, by Fisher's exact test. Survival curves were drawn up 
using the Kaplan-Meier method. Differences between survival 
times were analysed by the log rank method. 
Results 
In the current study we examined 99 specimens from patients 
with lung carcinomas. Tumors were classified according to their 
histological type: 41 adenocarcinomas, 41 squamous cell, 10 
undifferentiated large cell, 5 small cell and 2 adenosquamous 
carcinomas. According to the degree of histological 
differentiation: 7 well, 42 moderate and 33 poorly differentiated 
carcinomas. Tumors were also staged according to the TNM 
system as: 46 in stage I, 37 in stage II and 16 in stage III. 
Follow-up was available for 42 patients. 32 have died of the 
disease while 10 patients are still alive (after 1-63 months 
following surgery). Although no statistically significant 
correlations were found, the survival was shorter in patients 
with ras mutations (average survival 665.1 days), HPV infection 
(a.s. 718.2 days) and HPV infection simultaneously with ras 
mutations (a.s. 773.1 days), compared to those with no such 
alterations (a.s. 929.7, 956.7 and 871.2 days respectively). 
The type of HPV as well as the presence of point mutations 
in codon 12 of the K-ras gene were examined. The results of 
the PCR analysis are summarized in Table I. 
Fifteen of the 99 specimens (15%) were found positive for 
HPV. The prevalence of HPV infection was 20% in adeno­
carcinomas, 9.7% in squamous cell carcinomas, 20% in un­
differentiated large cell carcinomas, while HPV was also 
found in one of the two adenosquamous carcinomas. Results 
from the type distinction of HPV (Fig. 1) indicated that 
HPV 18 was the most frequent type (in 8% of the cases), 
while HPV 16 was found in 4%, HPV 11 in 3% and HPV 33 in 
2% of the cases examined (Table II). Samples found positive 
with the multiplex PCR (amplifying a region from the E6 
ORF) were also positive with the general primer PCR, 
indicating that the LI region was present. 
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Figure l. Type distinction of HPV employing a multiplex PCR. Products of 
different size (315 bp, HPV 16; 236 bp, HPV 11; 171 bp, HPV33; and 143 bp, 
HPV 18) were analysed by agarose gel electrophoresis. Lane M, molecular 
weight marker pUC18/HaeIII; lane 1, sample positive for HPV 11; lanes 
2,6, samples positive for HPV 18; lanes 3,7, samples positive for HPV 16; 





Figure 2. K-ras amplification products (157 bp) were digested with the 
restriction endonuclease BstNI and electrophoresed through an 8% 
Polyacrylamide gel. Lanes M, molecular weight marker pUCl8/HaeIII; 
lanes 1,11, positive control SW480 cell line (142 bp); lanes 2,12, undigested 
PCR product; lane 3, negative control; lanes 4,7-9, positive samples; lanes 
5,6,10, negative samples (113 bp). 
Table II. Incidence of HPV type in primary lung carcinomas. 








ain a total of 99 samples. 
K-ras codon 12 point mutations were found in 18 of the 
99 specimens (18%) examined (Fig. 2). Mutations were found 
in 8 (20%) of the 41 cases of adenocarcinoma, in 7 (17%) of 
the 41 cases of squamous cell carcinoma, in 2 (20%) of the 
10 cases of undifferentiated large cell carcinoma and in 1 of 
the 2 cases of adenosquamous carcinoma. 
The simultaneous presence of HPV DNA and K-ras 
mutation was observed in almost 50% of the HPV positive 
cases: in 9.8% of adenocarcinomas, in 7.3% of squamous cell 
carcinomas, in 10% of undifferentiated large cell carcinomas 
and in one of the two adenosquamous carcinomas. 
No correlation was found between HPV infection and K-ras 
mutation either with sex and age of the patient, or the histological 
type and the differentiation grade of the tumor. Survival curves 
determined by Kaplan-Meier method demonstrated that HPV 
infection and codon 12 point mutation of K-ras gene did not 
correlate with the clinical outcome of the patients. An association 
was found between K-ras codon 12 point mutations and the 
stage of the tumor, occuring more frequently at stage III 
(p=0.037) than stage I. These data suggest that infection with 
potentially oncogenic HPV types could be associated not only 
with anogenital tumors, but also with a subset of lung tumours, 
while HPV could co-operate with K-ras mutations in the 
progression of the disease. 
Discussion 
The potential role of HPV in the development of lung 
carcinomas emerged after the description of condylomatous-
like lesions in the bronchial epithelium adjacent to squamous 
cell carcinomas. Intranuclear HPV-like particles were 
demonstrated by electron microscopy in squamous cell 
papillomas of the bronchus (36). 
The presence of HPV in lung carcinomas has been reported 
in several studies. The rate of positivity varied between 4.2% 
and 31% (19-21), while in carcinomas with condylomatous 
changes the rate was higher (42%) (20). In contrast other 
investigators reported absence of HPV in lung cancer (37,38), 
this divergence may be due to the differences in the sensitivity 
and specificity of the methods applied, as well as to epidemio-
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logical factors. In the current study we confirm the presence 
of HPV in lung carcinomas, using primers from both the E6 and 
LI ORFs. The use of primers located in the E6 ORF, which 
remains intact in the case of high risk HPV type integration 
into the host genome, allows better diagnostic sensitivity. No 
difference was found in the detection rate of the virus using 
the two sets of primers from the E6 and LI ORFs. 
It is noteworthy that HPV was also detected in cases of 
adenocarcinoma. Recently, there has been increasing interest 
in the association between HPV and glandular neoplasia. In 
many studies HPV DNA has been found in adenocarcinomas 
and adenosquamous carcinomas as frequently as in squamous 
cell carcinomas of the cervix (39-41). 
In our study we found that multiple subtypes of HPV may be 
related to lung cancer. However HPV 18 was the predominant 
type, which is in agreement with other studies reporting that 
high-risk HPV types were more frequently detected (19,20,22). 
Their identification in both squamous cell carcinomas and 
adenocarcinomas as well as in adenosquamous and un­
differentiated large cell carcinomas suggests a key role in the 
process of lung carcinogenesis. Moreover, it has been suggested 
that infection with high risk HPVs could serve as a prognostic 
indicator of malignant progression in lung squamous cell 
papillomas (22). 
Multiple molecular changes have also been documented 
in lung cancer. These include activation of dominant onco­
genes, such as the ras gene family (23), myc and HER-2/new 
genes, as well as loss of recessive growth regulatory genes, 
or onco-suppressor genes (p53, rb) (23,26). 
Several studies have reported an incidence of 15-33% of 
activated K-ras gene in lung carcinomas, while more recent 
studies have revealed a higher incidence of more than 50% 
(42-44). In the current study we found K-ras codon 12 point 
mutations in 18% of the specimens examined. In cases of 
squamous cell carcinomas the incidence of K-ras mutations 
was higher than in other studies (24,42), propably due to the 
more sensitive assay used. Activation of the K-ras gene was 
examined, since point mutations of this member of the ras 
family are found more commonly in lung cancer and occur 
predominantly at codon 12. 
It has been suggested that K-ras mutations arise pre­
dominantly at the non-invasive stage of lung carcinogenesis, 
and may be associated with the transformation of dysplastic 
cells to neoplastic (45). Moreover, detection of K-ras mutations 
in sputum may precede diagnosis of lung cancer (29). On the 
other hand, a significant number of lung adenocarcinomas 
harbor ras mutations in only a small percentage of the cancer 
cells, indicating that K-ras mutations represent a late event in 
lung carcinogenesis (23). This concept is consistent with the 
association of ras mutations with increased tumor growth and 
invasiveness, as suggested by the poorer prognosis of mutation-
positive than mutation-negative cases treated by surgical 
resection (44,46). We found an association between K-ras 
mutations and the stage of the tumor, occuring more frequently 
at cases with stage III. However, no correlation was found 
between K-ras mutations and the clinical outcome of the 
patients examined. In 50% of the HPV-positive cases, K-ras 
mutation co-existed. This might suggest that HPV infection 
is not sufficient by itself for malignant transformation, but 
requires co-operation of an activated ras gene. In addition, 
carcinogen exposure may induce transformation in several 
fields of the bronchial epithelium through the induction of 
different genetic changes. 
Our results indicate that HPV infection and K-ras gene 
activation may play a role in a subset of lung tumors. The 
possibility of synergic mechanisms between HPV, ras gene 
mutations and chemical or physical carcinogens such as cigarette 
smoking should also be considered. 
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